Balyasny Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Balyasny Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-702,900	Closed	-$13M	–	3034
2023 Q3	$13M	Buy	+702,900	New	+$7.95M	0.03%	742

Balyasny Asset Management's ICPT Position: Q1 2023 in Review

Balyasny Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 364,068 shares — an estimated $4.5M sold.

Balyasny Asset Management first reported a position in ICPT in Q3 2016 and held it in 14 quarters. The position peaked at $13.8M in Q2 2017. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

Balyasny Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Balyasny Asset Management sold 364,068 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.5M.
Balyasny Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 14 quarters.
Balyasny Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $13.8M in Q2 2017.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.